The Oxford Dictionary defines anxiety as 'a feeling of worry, nervousness or unease about something with an uncertain outcome'. Multiple sclerosis (MS) can certainly be described as something with an uncertain outcome: a chronic neurological disorder that is unpredictable with recurrent relapses, seeming to occur at random, and the risk of eventual evolution to a chronically progressive disease after years or decades of stability. Thus, it is not surprising that the unpredictable nature of this disease, specifically with respect to relapses and the potential for future progression and disability, leads to anxiety. In the medical world, anxiety is defined as an excessive feeling of unease and worry that is persistent and leads to interference with every day functioning. It is different from fear, which is an emotional response to a (real or perceived) imminent threat. Anxiety involves the anticipation of a future (real or perceived) threat. Anxiety in persons with multiple sclerosis (PwMS) is common and can be severe; the prevalence of anxiety disorders has been reported to be as high as 36%. 1 A large survey study from a UK MS registry which included 7786 PwMS found that 54.1% reported symptoms of anxiety and met criteria for an anxiety disorder, with 49.0% of those reporting anxiety falling into a moderate or severe range. 2 Thus, although anxiety is an understandable and potentially predictable outcome of living with an unpredictable disease such as MS, the key for clinicians is to identify excessive or disproportionate anxiety that is lasting and having a significant impact on quality of life (QOL).
There are two main reasons why anxiety is more important than depression in PwMS. First, it remains remarkably understudied in the MS population. Recent systematic reviews have acknowledged identifying significantly fewer studies focusing on anxiety in MS as compared to depression; most of the studies that did include anxiety focused on both anxiety and depressive symptoms, while no studies focused solely on anxiety. In contrast, there were numerous studies focused solely on depression. 1, 3 Similarly, there were no controlled studies identified evaluating the effectiveness of interventions for anxiety disorders in MS, with only one trial reporting anxiety as a primary outcome (examination of injection phobia). 4 The lack of attention to this aspect of MS and the paucity of evidence-based treatments in the medical literature trickles down into medical practice. Clinicians often direct their time and attention towards available disease-modifying treatments or other visible physical symptoms, failing to recognize and treat anxiety, an often 'invisible' symptom, in the clinic setting. Furthermore, it can be difficult to recognize anxiety that is out of proportion to that which is expected in the context of situation stressors. Anxiety symptoms and anxiety disorders have a diverse clinical presentation, and the somatic symptomatology associated with anxiety can often be attributed to physical symptoms associated with MS. Yet, it has been reported that people with an anxiety disorder are three to five times more likely to visit their physician, either in the primary care or specialist setting. 5 It is clear that anxiety is under-recognized, understudied and under-treated in the MS population, which leads into the second reason why anxiety is more important than depression in MS. Although understudied, the available literature demonstrates the significant impact anxiety has on QOL and worsening of disease course and symptoms. Lack of recognition of anxiety as a symptom may lead to unnecessary trips to the MS clinic and may also be responsible for much of the distress in PwMS early and late in disease. Misdiagnosis or under-diagnosis of anxiety can lead to self-medication; there is a higher likelihood of alcohol abuse/dependence, substance abuse and smoking associated with anxiety in PwMS. 1 Anxiety has also been linked to suicidal intent and self-harm behaviours in PwMS. 6 Anxiety and stressful life events have been linked in PwMS, with the number of stressful events, not necessarily the severity of the event, linked to an increase in anxiety symptoms. Three (or more) stressful events significantly increase the risk of a relapse. 7 Furthermore, PwMS with anxiety report less adherence to both pharmacological and
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SA Morrow non-pharmacological therapies, leading to increased risk of relapse, disease progression and worsening symptomatology. Thus, PwMS are at an increased risk of relapse due to the potential interaction of these two factors. Finally, anxiety has been linked to many other common 'invisible' symptoms in PwMS. Studies have found that anxiety is associated with greater sleeping problems, and there is a higher prevalence of anxiety in PwMS who suffer from MS fatigue or pain. 8 Two studies have now clearly demonstrated a similar link between anxiety and cognitive impairment, as has been previously established between depressive symptoms and cognition. These studies showed a significantly lower performance on measures of processing speed and visual-spatial memory in PwMS with anxiety compared to non-anxious PwMS. 9,10 Finally, depression is a common co-morbid symptom with anxiety in PwMS, and anxiety has been found to be a strong predictor of depression both via direct and indirect pathways, suggesting a possible causal relationship. These findings further support the importance of addressing anxiety symptoms in PwMS as it will also likely lead to improvement in depression symptoms. More recently, the presence of co-morbidities and the presence of multiple co-morbidities in PwMS have garnered attention. Co-morbidity in PwMS significantly increases the risk of hospitalizations and mortality. 11 The fact that anxiety co-exists with many other co-morbid conditions, such as depression, fatigue and cognitive impairment, means it could act as a marker for other conditions, indicating the need to address non-physical symptoms to ensure stability in the course of MS.
Our goal as clinicians involved in the care of a PwMS is to promote an optimal QOL and disease stability in our patients. Thus, we should strive to identify those clinical conditions that co-occur with MS that have the most significant impact on QOL. Anxiety in PwMS has a significant negative effect through numerous pathways -medication adherence, poor coping mechanisms, increased risk of relapses and increased risk of other invisible symptoms such as comorbid depression, cognitive impairment and increased hospitalizations. Therefore, it is incumbent that those of us involved in the care of PwMS focus our clinical and research attention on this common and debilitating symptom with the aim of improving the well-being of PwMS.
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